Click here for slides on this topic


Angina

Chest pain due to lack of blood to the heart muscle.
The following content matched the glossary term: Angina

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

NDEI.org Expert Commentary on Look AHEAD trial Anne Peters

Top

Expert commentary on Look AHEAD trial from Anne Peters, MD.

Look AHEAD Trial Halted—Lifestyle Modifications Fail to Reduce CV Events in Patients With Diabetes  

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD)

Top

McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, Herman WH. Diabetes Care. Predictors of mortality over 8 years in type 2 diabetic patients Translating Research Into Action for Diabetes (TRIAD). 2012 Mar 19. Epub ahead of print. To examine demographic, socioeconomic, and biological risk factors for all-cause, cardiovascular, and noncardiovascular mortality in patients with type 2 diabetes over 8 years and to construct mortality prediction equations.

Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus

Top

Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2009;103(10):1364-1367. It is important identify patients with very high cardiovascular risk to intensify their therapy. Our aim was to assess the association between retinopathy and incident cardiovascular events (cardiovascular disease [CVD]) in patients with type 2 diabetes mellitus (DM).

Prevention of diabetes & cardiovascular disease in patients w/ impaired glucose tolerance: rationale & design of Nateglinide & Valsartan

Top

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623-632. Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle modification and medication can prevent or delay progression to diabetes (PD), but whether such interventions also reduce the risk of CVD has not been rigorously tested.

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes

Top

Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J. 2008;156(3):528-536. The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was undertaken to determine whether early revascularization intervention is superior to deferred intervention in the presence of aggressive medical therapy.

1 2 Next 

Slide Library Results

Search Results for: Angina Slides Found: 95
Diabetes and Post-MI Survival in Two Ethnic Groups
Elective Coronary Revascularization in Patients With Type 2 Diabetes
VADT: Comparing Intensive With Standard Glucose Therapy, Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
Medical Comorbidities Associated with Obesity
JUPITER: Design
JUPITER Analysis: Design
JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor*
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
JUPITER: Study Design
JUPITER: Lipid and HsCRP Levels
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
JUPITER Results: Summary
CHAMPION PHOENIX: Randomization
CHAMPION PHOENIX: Ischemic Endpoints
CHAMPION PHOENIX: Baseline Characteristics
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
Look AHEAD: No Reduction in CV Events with Lifestyle Changes
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Look AHEAD: Primary Outcome, Participant Characteristics
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Design
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Design
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines: Primary ASCVD Prevention for LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Statin Dosing
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
ACC/AHA Cholesterol Guideline 2013: Statin Safety Recommendations: Cognitive Impairment
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Bile-Acid Sequestrants & Ezetimibe
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Monitoring & Optimizing Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Treatment | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
Empagliflozin Safety Adverse Events Type 2 Diabetes EMPA-REG OUTCOME | NDEI
EMPA-REG OUTCOME Design Empagliflozin SGLT2 Type 2 Diabetes | NDEI
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
ACCELERATE Evacetrapib Does Not Lower CV Events in High-Risk Patients | NDEI
ACCELERATE Evacetrapib Doubles HDL-C & Lowers LDL-C CETP | NDEI
ACCELERATE CETP Inhibitor Trial Ended Early Due to Futility
Empagliflozin Reduces Kidney Disease in EMPA-REG OUTCOME CVOT | NDEI
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI